Skip to main content
. Author manuscript; available in PMC: 2016 Aug 22.
Published in final edited form as: Lancet Oncol. 2016 Jun 6;17(7):984–993. doi: 10.1016/S1470-2045(16)30146-2

Figure 2. Tumor responses to dabrafenib + trametinib in BRAF V600E–mutant non-small cell lung cancer.

Figure 2

Maximum reduction from baseline sum of lesion diameters by best investigator-assessed confirmed response in ≥ second-line patients (n=57). CR=complete response. NE=not evaluable. PD=progressive disease. SD=stable disease.